Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX.
Clin Breast Cancer. 2013 Oct;13(5):325-34. doi: 10.1016/j.clbc.2013.02.014. Epub 2013 Jun 28.
The M. D. Anderson Symptom Inventory (MDASI) is a psychometrically validated patient-reported outcome measurement that assesses the severity and impact of multiple symptoms related to cancer and its treatment. With the MDASI, patients rate 13 common "core" symptoms and 6 items that reflect symptom interference with functioning. Several MDASI modules (core symptom and interference items plus additional symptoms specific to a particular cancer type or treatment modality) have been developed. Although the original MDASI validation study encompassed various cancer types, the instrument's psychometric properties have not been examined in a homogenous sample of patients with breast cancer in a national multicenter study.
We performed a secondary analysis of data from an Eastern Cooperative Oncology Group study to establish the reliability, validity, and sensitivity of the MDASI in a large sample of patients with breast cancer (n = 1544), 78% of whom were receiving treatment. The instrument was administered twice, approximately 1 month apart.
Internal consistency and test-retest reliability were adequate, with Cronbach α values ≥ 0.85 and intraclass correlations ≥ 0.76 for all subscales. Known-group validity was evaluated by using performance status, tumor response, and disease stage. Sensitivity to change in patient-reported quality of life was established.
The MDASI is a valid, reliable, and sensitive symptom-assessment instrument that can enhance descriptive and clinical studies of symptom status in patients with breast cancer. Future studies might include cognitive debriefing and qualitative interviews to identify additional disease-specific items for inclusion in a MDASI breast cancer module.
MD 安德森症状指数（MDASI）是一种经过心理测量验证的患者报告的结果测量，用于评估与癌症及其治疗相关的多种症状的严重程度和影响。使用 MDASI，患者对 13 种常见的“核心”症状和 6 项反映症状对功能的干扰的项目进行评分。已经开发了几种 MDASI 模块（核心症状和干扰项目加上特定于特定癌症类型或治疗方式的其他症状）。尽管原始 MDASI 验证研究涵盖了多种癌症类型，但该工具的心理测量特性尚未在一项全国多中心研究中对同质的乳腺癌患者样本进行检查。
我们对东部合作肿瘤学组研究的数据进行了二次分析，以在一个大型乳腺癌患者样本（n = 1544）中建立 MDASI 的可靠性、有效性和敏感性，其中 78%的患者正在接受治疗。该仪器大约相隔一个月进行两次测量。
所有子量表的内部一致性和测试-重测信度均足够，克朗巴赫 α 值≥0.85，组内相关系数≥0.76。使用表现状态、肿瘤反应和疾病阶段评估了已知组别的有效性。确立了对患者报告的生活质量变化的敏感性。
MDASI 是一种有效的、可靠的、敏感的症状评估工具，可以增强对乳腺癌患者症状状况的描述性和临床研究。未来的研究可能包括认知性询问和定性访谈，以确定包括在 MDASI 乳腺癌模块中的其他特定于疾病的项目。
